During a Targeted Oncology Case Based Peer Perspectives event, John K. Chan, MD, reviewed the case of a 49-year-old African American woman with high-grade epithelial ovarian cancer.
Targeted Oncology Staff
Articles by Targeted Oncology Staff
Thomas C. Krivak, MD, interpreted the results clinical trials of bevacizumab as treatment of patients with ovarian cancer to determine the optimal treatment strategy for a 69-year-old patient.
During a Targeted Oncology Case Based Peer Perspective event, John Heymach, MD, PhD Chair, Department of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center, discusses the case of a 73-year-old Asian patients with EGFR-mutant non–small cell lung cancer.
Jun Zhang, MD, PhD, associate professor, University of Kansas Medical Center, reviews the preferred treatment options for extensive-stage small cell lung cancer in a 73-year-old patient during a Targeted Oncology Case Based Peer Perspective event.
During a Targeted Oncology Case Based Peer Perspectives event, Miguel-Angel Perales, MD, discussed testing for risk stratification and treatment of graft-versus-host-disease based on the case of a 48-year-old man.
During a Targeted Oncology Case Based Peer Perspectives event Karen L. Kelly, MD, discussed molecular testing guidelines and testing execution for early-stage non–small cell lung cancer as well as the research supporting the use of targeted therapies for treatment.
During a Targeted Oncology Case Based Peer Perspectives event, Daniel J. George, MD, professor of Medicine, professor in Surgery Member, Duke Cancer Institute Department of Medicine Duke University School of Medicine, discuss various hormonal therapies for the treatment of prostate cancer.
During a Targeted Oncology Case Based Peer Perspectives event, Andrew Kuykendall, MD, assistant member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, discussed the use of ruxolitinib as treatment of 67-year-old patients with polycythemia vera.
Loretta J. Nastoupil, MD, discussed the use of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma during a Targeted Oncology Case Based Peer Perspectives event.
During a Targeted Oncology Case Base Peer Perspective event, Ian W. Flinn, MD, PhD, compares the combination of tafasitamab-cxix plus lenalidomide, and selinexor as treatment of relapsed or refractory diffuse large B-cell lymphoma to other other available regimens.
During a Targeted Oncology Case Based Peer Perspectives event, Marc Matrana, MD, MS, discussed the case of a 62-year-old male patients with renal cell carcinoma.
The results from the phase 3 CASPIAN trial were reviewed and compared with the phase 3 IMpower133 by Jyoti D. Patel, MD, during a Targeted Oncology Case Based Peer Perspectives event.
Comparing the efficacy of selective HER2 kinase inhibitors in HER2-positive metastatic breast cancer, it was shown that tucatinib may have been approved in the second-line setting due to it's unique impact on the central nervous system. Another HER2 inhibitor, trastuzumab deruxtecan has demonstrated promise in a phase 2 study and is now being confirmed in a phase 3 study.
During a Targeted Oncology Case Based Peer Perspectives event, Antoinette Wozniak, MD, discussed the case of a 59-year-old man with non-small cell lung cancer.
Matthew Taylor, MD, reviewed the clinical trials supporting levantinib as a treatment option for a patient with thyroid cancer and discussed the option with a group of oncologists during a Targeted Oncology Case Base Peer Perspectives event.
During a Targeted Oncology Case Based Peer Perspectives event, Rami Komrokji, MD, explored the use of ruxolitinib (Jakafi) for the treatment of a 68-year-old female patient with myelofibrosis.
Kami J. Maddocks, MD, discussed the efficacy and safety of tafasitamab in combination with lenalidomide as treatment of a 74-year-old man with diffuse large B-cell lymphoma. The treatment option was discussed with a group of oncologists during a Targeted Oncology Case Based Peer Perspective event.
During a Targeted Oncology Case Based Peer Perspectives event, Marcia S. Brose, MD, PhD, discussed options for a 58-year-old patient with RET-mutant medullary thyroid cancer.
Michael A. Carducci, MD, provided recommendations for treatment of a 75-year-old man with castrastion-resistant prostate cancer.
During a Targeted Oncology Case Based Peer Perspectives event, Alicia K. Morgans, MD, MPH, reviewed 2 cases of patients with nonmetastatic castration resistant prostate cancer and explained the potential testing and treatment options.
During the Targeted Oncology Case Based Peer Perspectives event, Javier L. Munoz, MD, Hematologist/Oncologist Director, Lymphoma Program Mayo Clinic, discussed the case of 60-year-old patient with peripheral T-cell lymphoma.
During a Targeted Oncology Case Based Peer Perspective event, Erlene Seymour, MD, reviewed the front-line treatment options for chronic lymphocytic leukemia.
During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.
During a Targeted Oncology Case Based Peer Perspective event, Usama Gergis, MD, MBA, discussed the case of a 48-year-old male patient with acute graft-versus-host-disease.
During a Targeted Oncology Case Based Peer Perspectives event, Farrukh Awan, MD, discussed the various treatment options for a 61-year-old patient with high-risk chronic lymphocytic leukemia.
During a Targeted Oncology Case Based Peer Perspective event, Gino K. In, MD, MPH, assessed the risk status of an 88-year-old patient with basal cell carcinoma and discussed treatment options.
In the treatment of EGFR-mutant non–small cell lung cancer, oncologists face multiple challenges with prescribing medications to patients. During a Targeted Oncology Case Based Peer Perspective event, Nathan Pennell, MD, PhD, discussed these challenges as well as potential treatment approaches with a group of peers.
In an interview with Targeted Oncology, Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discussed the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.
Lyudmila Bazhenova, MD, led a peer discussion about the frontline treatment options for a middle-aged male patient with ALK-positive non–small cell lung cancer.
A selection of therapies exist for patients with oncogene-driven lung cancer. Ticiana Leal, MD, discussed these options with a group of peers during a Targeted Oncology Case Based Peer Perspectives event.